Frederic Kaye
Affiliations: | The George Washington University, Washington, DC, United States |
Area:
Genetics, Oncology, Molecular BiologyGoogle:
"Frederic Kaye"
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Guijarro MV, Nawab A, Dib P, et al. (2023) TYMS promotes genomic instability and tumor progression in Ink4a/Arf null background. Oncogene |
| Khan S, Kellish P, Connis N, et al. (2023) Co-targeting BCL-X and MCL-1 with DT2216 and AZD8055 synergistically inhibit small-cell lung cancer growth without causing on-target toxicities in mice. Cell Death Discovery. 9: 1 |
| Khan S, Wiegand J, Zhang P, et al. (2022) BCL-X PROTAC degrader DT2216 synergizes with sotorasib in preclinical models of KRAS-mutated cancers. Journal of Hematology & Oncology. 15: 23 |
| Creelan BC, Wang C, Teer JK, et al. (2021) Tumor-infiltrating lymphocyte treatment for anti-PD-1-resistant metastatic lung cancer: a phase 1 trial. Nature Medicine |
| Zhou X, Li JW, Chen Z, et al. (2021) Dependency of human and murine LKB1-inactivated lung cancer on aberrant CRTC-CREB activation. Elife. 10 |
| Chen Z, Ni W, Li JL, et al. (2021) The CRTC1-MAML2 fusion is the major oncogenic driver in mucoepidermoid carcinoma. Jci Insight. 6 |
| George TJ, DeRemer DL, Parekh HD, et al. (2020) Phase II trial of the PARP inhibitor, niraparib, in BAP1 and other DNA damage response (DDR) pathway deficient neoplasms including cholangiocarcinoma. Journal of Clinical Oncology. 38: TPS591-TPS591 |
| ali a, DeRemer DL, Lee J, et al. (2020) Phase II trial of the PARP inhibitor, niraparib, in BAP1 and other DNA damage response (DDR) pathway deficient neoplasms (NCT03207347). Journal of Clinical Oncology. 38: e22061-e22061 |
| Stewart BD, Kaye F, Machuca T, et al. (2019) SMARCA4-Deficient Thoracic Sarcoma: A Case Report and Review of Literature. International Journal of Surgical Pathology. 1066896919865944 |
| Tasoulas J, Rodon L, Kaye FJ, et al. (2019) Adaptive Transcriptional Responses by CRTC Coactivators in Cancer. Trends in Cancer. 5: 111-127 |